Academic title (Akademischer Titel):
PD. Dr. med.

Date of birth (Geburtsdatum): 
09.07.1970

Nationality (Nationalität):
German

Present position (Gegenwärtige Position):
Oberärztin in der Interdisziplinären Klinik und Poliklinik für Stammzelltransplantation (Direktor Prof. Dr. Dr. h.c. Zander) im Universitätsklinikum Hamburg-Eppendorf

Schullaufbahn, Studium und Promotion

1977-1980
Grundschulen Birkach und Garching bei München

1980-1990
Werner-Heisenberg-Gymnasium Garching

29.06.1990
Abitur; Note: 1,0.

1990 - 1997
Studium der Humanmedizin an der Technischen Universität München

1990 - 1997
Stipendium der Bayerischen Begabtenförderung

06.05.1997
Drittes Staatsexamen; Note: sehr gut.

10.02.2000
Promotion: „Die Pierre-Robin-Sequenz beim Säugling, Klinik, morphometrische Analyse und Therapie“; Prof. Dr. G. Göz, Zahn-, Mund- und Kieferklinik der Universität Tübingen; Bewertung: magna cum laude.

Beruflicher Werdegang

01.07.1997 – 31.12.1998
Internistische Weiterbildung:
Abteilung für Gastroenterologie des Städtischen Krankenhauses München-Bogenhausen; Direktor Prof. Dr. W. Schepp

01.01.1999 - 30.06.2003
Internistische Abteilung des Kreiskrankenhauses Erding; Schwerpunkte: Pulmonologie; Gastroenterologie; Internistische Intensivmedizin; Direktor Prof. Dr. H.-P. Emslander  
Weitere Abschlüsse: Fachkunde Notarztwesen, Fachkunde Strahlenschutz

01.07.2002 - 31.09.2005
Hämatologische Weiterbildung in der Medizinischen Klinik III des Klinikums Großhadern (Direktor Prof. Dr. W. Hiddemann); Schwerpunkte: Hämato-Onkologische Privatstation (Oberarzt Prof. Dr. H. Ostermann); Abteilung für Knochenmark- und Stammzell-transplantation (Oberarzt Prof. Dr. J. Kolb)

23.11.2003
Facharztprüfung Innere Medizin

02.02.2005
Schwerpunktbezeichnung Hämatologie / Internistische Onkologie

01.10.2005 – 30.11.2005
Abteilung für Klinische Chemie; Institut für Klinische Chemie des Klinikums Grosshadern; Direktor Prof. Dr. Dr. D. Seidel (Schwerpunkte: Zytomorphologie, Immun-phänotypisierung)

seit 01.12.2006
Oberärztin in der Interdisziplinären Klinik und Poliklinik für Stammzelltransplantation (Direktor Prof. Dr. Dr. h.c. Zander) im Universitätsklinikum Hamburg-Eppendorf

18.09.2008
Habilitation für das Fach Innere Medizin

01.07.2002 – 31.12.2005
Betreuung von hämatologischen Studien in der Medizinischen Klinik III des Klinikums Grosshadern (Hodgkin-Studie, Hoelzer-ALL-Studien)

01.07.2002 – 31.07.2005
Mitarbeit im Labor für Leukämiediagnostik (Prof. Dr. Dr. T. Haferlach, PD Dr. C. Schoch, PD Dr. W. Kern, PD Dr. S. Schnittger) an der Medizinischen Klinik III des Klinikums Grosshadern (Prof. Dr. W. Hiddemann).
(Zytomorphologie, Chromosomenanalyse, Interphase-FISH. Korrelation verschiedener Methoden in der hämatologischen Diagnostik, Auswertung diagnostischer Methoden im Hinblick auf ihre prognostische Wertigkeit.)

Aktuellste Veröffentlichungen finden Sie auch unter: Bacher, Ulrike

(Stand 17.03.2009)

1. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G, Lellek H, Schrum J, Erttmann R, Eiermann T, Zander A.
Biol Blood Marrow Transplant. 2009 Apr;15(4):454-62.

2. Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors.
Ocheni S, Zabelina T, Bacher U, Ayuk F, Zander A, Kroger N.
Leuk Lymphoma. 2009 Mar 4:1-7.

3. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Schnittger S, Bacher U, Haferlach C, Geer T, Müller P, Mittermüller J, Petrides P, Schlag R, Sandner R, Selbach J, Slawik HR, Tessen HW, Wehmeyer J, Kern W, Haferlach T.
Haematologica. 2009 Mar;94(3):414-8.

4. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A.
Blood. 2009 Feb 19;113(8):1866-8.

5. Discussion of the applicability of microarrays: profiling of leukemias.
Haferlach T, Bacher U, Kohlmann A, Haferlach C.
Methods Mol Biol. 2009;509:15-33.

6. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.
Haferlach T, Kohlmann A, Klein HU, Ruckert C, Dugas M, Williams PM, Kern W, Schnittger S, Bacher U, Löffler H, Haferlach C.
Leukemia. 2009 Feb 5.

7. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
Schafhausen P, Dierlamm J, Bokemeyer C, Bruemmendorf TH, Bacher U, Zander AR, Schnittger S, Hochhaus A.
Cancer Genet Cytogenet. 2009 Feb;189(1):63-7.

8. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kröger N.
Exp Hematol. 2009 Jan;37(1):135-42.

9. Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies.
Bacher U, Schnittger S, Grüneisen A, Haferlach T, Kern W, Haferlach C.
Cancer Genet Cytogenet. 2009 Jan 15;188(2):108-11.

10. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, Fries S, Knoblich J, Köchling G, Laubenstein HP, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T.
Haematologica. 2009 Jan;94(1):141-4.

11. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A.
Cancer Genet Cytogenet. 2008 Dec;187(2):101-11.

12. Outcome of allo-SCT for chronic myelomonocytic leukemia.
Ocheni S, Kröger N, Zabelina T, Zander AR, Bacher U.
Bone Marrow Transplant. 2008 Nov 10.

13. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander AR.
Biol Blood Marrow Transplant. 2008 Aug;14(8):913-9.

14. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
Bacher U, Zander AR, Haferlach T, Schnittger S, Fehse B, Kröger N.
Bone Marrow Transplant. 2008 Aug;42(3):145-57.

15. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.
Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander AR, Bacher U.
Bone Marrow Transplant. 2008 Aug;42(3):181-6.

16. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander AR.
Exp Hematol. 2008 Aug;36(8):1047-54.

17. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón JA, Gutierrez NC, Bethge W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Penas EM, Dierlamm J, Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Nagler A, Kröger N.
Leukemia. 2008 Jun;22(6):1250-5.

18. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.
Lioznov M, Badbaran A, Fehse B, Bacher U, Zander AR, Kröger NM.
Bone Marrow Transplant. 2008 May;41(10):913-6.

19. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S.
Blood. 2008 Mar 1;111(5):2527-37.

20. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C.
Ann Hematol. 2008 Jan;87(1):1-10.

21. Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C.
Med Klin (Munich). 2007 Sep 15;102(9):770-7.

22. A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.
Schnittger S, Bacher U, Kern W, Haferlach T, Hertenstein B, Haferlach C.
Leukemia. 2008 Apr;22(4):856-8.

23. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
Schnittger S, Bacher U, Haferlach C, Dengler R, Kröber A, Kern W, Haferlach T.
Leukemia. 2008 Feb;22(2):453-5.

24. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S.
Haematologica. 2007 Jun;92(6):744-52.

25. A new interphase fluorescence in situ hybridization approach for genomic rearrangements involving MLH1 and MSH6 in hereditary nonpolyposis colorectal cancer-suspected mutation-negative patients.
Koehler U, Grabowski M, Bacher U, Holinski-Feder E.
Cancer Genet Cytogenet. 2007 May;175(1):81-4.

26. A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Bacher U, Haferlach T, Kern W, Harich HD, Schnittger S, Haferlach C.
Cancer Genet Cytogenet. 2007 May;175(1):52-6.

27. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
Schnittger S, Bacher U, Kern W, Haferlach T, Haferlach C.
Leukemia. 2007 Aug;21(8):1843-5.

28. Diagnostic pathways in acute leukemias: a proposal for a multimodal approach.
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C.
Ann Hematol. 2007 May;86(5):311-27.

29. Long-term safety of filgrastim (rhG-CSF) administration: application of haematopoietic growth factors in healthy individuals.
Bacher U, Zander AR.
Br J Haematol. 2007 Apr;137(1):78-9; author reply 79-80.

30. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Schnittger S, Bacher U, Haferlach C, Kern W, Haferlach T.
Leukemia. 2007 Apr;21(4):725-31.

31. Insight into the molecular pathogenesis of myeloid malignancies.
Haferlach T, Bacher U, Haferlach C, Kern W, Schnittger S.
Curr Opin Hematol. 2007 Mar;14(2):90-7.

32. Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application
Haferlach T, Bacher U, Kohlmann A, Schnittger S, Kern W, Haferlach C.
Med Klin (Munich). 2006 Nov 15;101(11):908-14.

33. Gene expression profiling for the diagnosis of acute leukaemia.
Haferlach T, Kohlmann A, Bacher U, Schnittger S, Haferlach C, Kern W.
Br J Cancer. 2007 Feb 26;96(4):535-40.

34. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
Schnittger S, Bacher U, Kern W, Haferlach C, Haferlach T.
Leukemia. 2007 Jan;21(1):183-4. Epub 2006 Nov 9.

35. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E.
Schnittger S, Bacher U, Kern W, Schröder M, Haferlach T, Schoch C.
Leukemia. 2006 Dec;20(12):2195-7.

36. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Bacher U, Schnittger S, Kern W, Trenn G, Weisser M, Haferlach T, Schoch C.
Cancer Genet Cytogenet. 2006 Jul 15;168(2):172-4.

37. A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.
Bacher U, Reiter A, Haferlach T, Mueller L, Schnittger S, Kern W, Schoch C.
Haematologica. 2006 Jun;91(6):817-20.

38. Implications of NRAS mutations in AML: a study of 2502 patients.
Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S.
Blood. 2006 May 15;107(10):3847-53.

39. Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
Bacher U, Kern W, Schoch C, Schnittger S, Hiddemann W, Haferlach T.
Cancer. 2006 Feb 15;106(4):839-47.

40. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
Bacher U, Kern W, Schnittger S, Hiddemann W, Haferlach T, Schoch C.
Haematologica. 2005 Nov;90(11):1502-10.

41. Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients.
Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T.
Ann Hematol. 2005 Nov;84(12):785-91.

42. Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.
Bacher U, Haferlach T, Schoch C.
Cancer Genet Cytogenet. 2005 Jul 15;160(2):179-83.

43. The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
Bacher U, Schnittger S, Kern W, Hiddemann W, Haferlach T, Schoch C.
Haematologica. 2005 Apr;90(4):558-9.

44. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
Bacher U, Haferlach T, Kern W, Hiddemann W, Schnittger S, Schoch C.
Ann Hematol. 2005 Apr;84(4):250-7.

45. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.
Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W, Schoch C.
Cancer Genet Cytogenet. 2005 Feb;157(1):53-61.

46. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha.
Bacher U, Hochhaus A, Berger U, Hiddemann W, Hehlmann R, Haferlach T, Schoch C.
Leukemia. 2005 Mar;19(3):460-3.

47. Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia.
Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T.
Leuk Lymphoma. 2005 Mar;46(3):357-66.

48. Erythroblastic synartesis in a patient initially diagnosed with myelodysplastic syndrome.
Bacher U, Lenz G, Haferlach T, Loeffler H, Moosmann N, Hiddemann W, Ostermann H.
Ann Hematol. 2005 Apr;84(4):272-3.

49. Discrimination of chronic lymphocytic leukemia (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic markers as investigated by interphase fluorescence in situ hybridization (FISH).
Bacher U, Kern W, Schoch C, Hiddemann W, Haferlach T.
Ann Hematol. 2004 Jun;83(6):349-55.

50. Three-dimensional computer morphometry of the maxilla and face in infants with Pierre Robin sequence--a comparative study.
Bacher M, Bacher U, Göz G, Pham T, Cornelius CP, Speer CP, Goelz R, Arand J, Wendling F, Buchner P, Bacher A.
Cleft Palate Craniofac J. 2000 May;37(3):292-302.

51. Three-dimensional analysis of cleft palate topology in newborn infants with reference to the cranial skeleton.
Bacher M, Göz G, Pham T, Bacher U, Werner O, Buchner P, Bacher A.
Cleft Palate Craniofac J. 1998 Sep;35(5):379-95.